News Category
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher's clinical research business to initiate Phase 2 testing of Lucid-MS, a fir...
Regentis Biomaterials is developing GelrinC, an off-the-shelf hydrogel implant designed to regenerate knee cartilage, addressing a significant unmet n...
American Fusion Inc. has moved its Texatron fusion program from prototype development into active testing, achieving peak confinement pressures of app...
The Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference will bring together emerging and under-covered companies with investors,...
SuzieQ Holdings' participation in the Moody Capital conference highlights its focus on post-quantum cryptography and the capital needed to scale natio...
A new study confirms that treating selected ER patients while seated, rather than waiting for a bed, significantly reduces wait times, potentially low...
Helus Pharma reports progress in its Phase 3 trials for HLP003, with topline data expected in Q4 2026, and advances HLP004 for generalized anxiety dis...
Helus Pharma's appointment of Michael Halstead as CEO signals strategic leadership for its Phase 3 development and potential commercialization, markin...
Ocumetics Technology Corp. has completed the second tranche of its private placement, raising $2.5 million to fund its first-in-human clinical trials ...
VERAXA Biotech AG shareholders approved governance and financing changes with over 99.94% support, enabling greater flexibility for growth and pipelin...
VERAXA Biotech announced the advancement of its bispecific antibody-drug conjugate program VXA-222, which uses an AND-gate approach to improve precisi...
Gerresheimer's new plant in Zhenjiang Dagang, China, doubles production capacity for primary glass packaging for injectable pharmaceuticals, respondin...
Darwin AG has changed its name to Novogenia AG to unify its corporate and brand identities, reflecting its strategic focus on personalized healthcare ...
NanoViricides is moving its oral gummies formulation of NV-387 toward a Phase II trial for the Bundibugyo ebolavirus outbreak in the DRC, where no app...
Redwood AI Corp. has been added to the CSE25 Index, reflecting its market capitalization growth and potentially increasing visibility among investors ...
Helus Pharma announced fiscal 2026 financial results and progress on its Phase 3 trial for HLP003, a major depressive disorder treatment, with topline...
Quantum BioPharma is advancing Lucid-MS, a drug candidate that directly targets myelin repair, into Phase 2 trials, addressing the critical unmet need...
Nanomedicine and advanced drug-delivery platforms like Oncotelic Therapeutics' Deciparticle(TM) are emerging as a cost-effective strategy to enhance e...
Quantum BioPharma's Lucid-MS, a novel neuroprotective therapy for multiple sclerosis, is progressing to Phase 2 trials after demonstrating safety and ...
VERAXA Biotech announced in vitro proof-of-concept data for its BiTAC-ADC platform, which selectively kills breast cancer cells while sparing healthy ...
Redwood AI Corp. is highlighted as a company to watch due to its proprietary AI platforms that aim to expedite chemistry research and development in p...
NanoViricides has received approval from the Democratic Republic of Congo's Pillar Committee to proceed with a Phase II clinical trial for its oral Eb...
Helus Pharma's Chief Medical Officer will discuss the company's novel serotonergic agonists for depression and anxiety at the upcoming H.C. Wainwright...
Onco-Innovations Limited initiates process development and scale-up for ONC010's active ingredient, a critical step toward IND-enabling studies and fi...
Quantum BioPharma's LUCID-MS program, targeting myelin repair in multiple sclerosis, completed Phase 1 trials showing safety and tolerability, address...
NeuroOne Medical Technologies will present at the Planet MicroCap Las Vegas 2026 Conference on June 17, 2026, providing commercialization updates and ...
GeoVax Labs CEO David Dodd comments on recent pharmaceutical industry acquisitions, emphasizing the growing strategic importance of vaccine innovation...
Quantum BioPharma's lead drug candidate Lucid-MS aims to address mobility loss in multiple sclerosis by targeting nerve damage, while its commercial p...
Helus Pharma announced its participation in the Jefferies Global Healthcare Conference, where interim CEO Eric So will discuss the company's clinical-...
TransCode Therapeutics has launched a Phase 2a trial of TTX-MC138 in colorectal cancer patients with minimal residual disease, aiming to reduce recurr...
NanoViricides announces that its broad-spectrum antiviral NV-387 warrants evaluation for the Bundibugyo Ebola strain, with potential advantages in out...
SureNano Science Ltd. is advancing its novel GLP-1 therapeutic GEP-44, acquired through GlucaPharm Inc., aiming to compete in the rapidly growing mark...
Oncotelic Therapeutics' integration of 28 million scientific abstracts into its PDAOAI platform underscores the growing importance of AI in drug disco...
Telomir Pharmaceuticals announced publication of preclinical data showing Telomir-Zn improves survival and reduces liver copper in Wilson’s disease, e...
Lantern Pharma announced FDA support for protocol amendments in its Phase 2 HARMONIC trial, potentially accelerating development of LP-300 for a speci...
NanoViricides highlights its oral drug candidate NV-387's potential against the Bundibugyo Ebola outbreak, emphasizing its broad-spectrum mechanism ta...
Quantum BioPharma announced that its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached midpoint enrollmen...
LIXTE Biotechnology Holdings reports first-quarter progress on its lead candidate LB-100 and the expansion of its subsidiary Liora Technologies, signa...
Dogwood Therapeutics announced first quarter 2026 financial results, highlighting strong pipeline progress with Phase 2b data for Halneuron expected i...
Innovative nose-to-brain delivery platforms are overcoming the blood-brain barrier, potentially transforming treatment for neurological diseases and u...
Silo Pharma announced a strategic initiative to develop ibogaine-based therapeutics for traumatic brain injury and related conditions, filing a provis...
Three fatalities from hantavirus on the MV Hondius cruise ship highlight the dangers of this little-known infection, prompting a need for understandin...
NanoViricides announced that its broad-spectrum antiviral drug NV-387 has been granted Orphan Drug Designation by the FDA for measles, offering incent...
VolitionRx announced successful detection of nucleosomes in capillary blood from sepsis patients using a lateral flow finger-prick prototype, potentia...
Helus Pharma collaborates with TARA Mind and VETS to recruit veterans for its Phase 3 PARADIGM trial of HLP003, a Breakthrough Therapy-designated trea...
Ventripoint Diagnostics and its partner Lishman Global have submitted the VMS+ 4.0 system for NMPA approval in China, with a green channel designation...
Formycon AG will publish its FY2025 results on April 22, 2026, and host a conference call, while also outlining its participation in key international...
The appointment of Dr. Ken Kramer, a veteran in neuroscience medical affairs, signals Helus Pharma's strategic push to accelerate its clinical program...
